Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Void who wrote (23280)	7/16/1998 12:20:00 PM
From: Henry Niman	Respond to of 32384

V, I think that there is a bit on confusion with regard to the pipeline as well as what exactly a "human-active" G-CSF mimic is. The table that I put up at home.att.net is not a table that is predicting anything. It comes from LGND's 1997 annual report and it merely represents progress to date (i.e. the progress has already happened). The above table is a more graphical version of the table at home.att.net which is actually taken from LGND's SEC filing: edgar-online.com The molecule defined in the Science paper was deemed to be mouse-specific because it mimicked G-CSF in mouse cell lines and animals, but did not work in human cell lines. It was not placed into patients but the molecule that does enter the clinic will be tested on human cell lines in pre-clinical tests. I think that LGND does indeed have a molecule that is human-active which was based on human cell lines. Obviously there have been no human trials yet. The human-reactive molecule has not been announced and an IND has not been filed.